News

Common sense drives risk factor screening for systemic psoriasis therapy


 

EXPERT ANALYSIS FROM SDEF LAS VEGAS DERMATOLOGY SEMINAR

References

Dr. Duffin reported receiving research support from and consulting for Amgen, Eli Lilly, Janssen, Stiefel, AbbVie, Bristol-Myers Squibb, Celgene, Novartis, and XenoPort; consulting and being on the scientific advisory board for Pfizer; and being on the scientific advisory board for Novartis, Eli Lilly, Janssen, Celgene, and XenoPort.

SDEF and this news organization are owned by the same parent company.

koakes@frontlinemedcom.com

On Twitter @karioakes

Pages

Recommended Reading

EADV: Ixekizumab promising for psoriatic arthritis
MDedge Dermatology
EADV: Long-term apremilast results show what to expect for psoriasis
MDedge Dermatology
EADV: Spotlight on alexithymia in psoriasis
MDedge Dermatology
EADV: Secukinumab shows sustained high efficacy in SCULPTURE through 3 years
MDedge Dermatology
EADV: No cancer signal with ixekizumab
MDedge Dermatology
Depression and Psoriasis
MDedge Dermatology
Shingles vaccine protection lasted 5-6 years in autoimmune disease patients
MDedge Dermatology
Stroke risk rose in autoimmune disease patients after herpes zoster
MDedge Dermatology
Can bariatric surgery ease psoriasis too?
MDedge Dermatology
VIDEO: Psoriasis, psoriatic arthritis improve with bariatric surgery
MDedge Dermatology